酵素替代疗法市场－全球产业规模、份额、趋势、机会及预测（按产品、疾病、给药途径、最终用户、地区和竞争格局划分，2021-2031年）

全球酵素替代疗法市场预计将从 2025 年的 107.3 亿美元成长到 2031 年的 168.5 亿美元，复合年增长率为 7.81%。

酵素替代疗法是治疗罕见遗传疾病（主要是溶小体储积症症）患者的重要治疗选择，用于补充缺失或不足的酵素。市场成长的驱动因素包括：已确诊遗传疾病盛行率的上升、重组DNA技术的进步使得人类酵素的大规模生产成为可能，以及孤儿药认定等政府支持性法规。这些驱动因素共同推动市场扩张，维持强大的开发平臺，并满足了以往服务不足的患者群体的需求。

然而，由于研发和治疗治疗方法高成本，该领域面临许多挑战，这往往导致报销困难和病患用药受限。儘管存在这些经济障碍，该行业仍然致力于创新。根据美国药品研究与製造商协会（PhRMA）统计，到2024年，将有超过560种针对罕见疾病的新药正在研发中，其中包括酵素缺乏症的治疗方法，这表明该行业在解决这些复杂的疾病方面持续投入。

市场驱动因素

监管核准流程和孤儿药认定是重要的市场成长催化剂，能够降低罕见疾病治疗药物研发相关的财务风险。监管机构提供市场独占权、临床试验税额扣抵和快速审批等重要奖励，促使製药公司儘管患者群体较小，仍致力于开发酶缺乏症的治疗药物。这种支持在近期监管机构对服务不足疾病治疗方法的优先审批中得到了充分体现。例如，美国食品药物管理局（FDA）药物评估与研究中心在其2024年1月发布的《2023年新药核准情况报告》中指出，2023年核准的55种新药中有28种被认定为孤儿药，凸显了这些核准途径在新型罕见病治疗药物商业化过程中发挥的重要过程。

同时，强大的临床试验管线和策略性研发投资正在提升酵素替代疗法的可近性和疗效。製药公司正集中资源开发新一代製剂，以提高组织标靶性和稳定性，并透过内部成长和收购积极拓展市场份额。这一发展势头带来了可观的财务回报，并扩大了全球患者的用药范围。根据Change Group于2024年4月发布的2023年度报告，该公司罕见疾病部门的销售额达到5.4亿欧元，以外汇汇率计算成长了65%，这主要得益于其不断扩大的产品组合。同样，BioMarin Pharmaceuticals于2024年2月宣布，其2023年全年总收入将达到24.2亿美元，比上年增长15%，进一步印证了该业务板块的强劲财务实力。

市场挑战

酵素替代疗法（ERT）的研发和应用成本高昂，构成了严重的报销障碍，并直接阻碍了市场扩张。这些复杂的生物製剂生产难度高，且目标患者群较小，导致每位患者的治疗费用居高不下，对医疗预算造成巨大压力。因此，无论是私人还是公共支付方，都经常采取严格的成本控制措施，包括漫长的价格谈判和严格的报销标准。这些财务障碍阻碍了已通过核准治疗方法的顺利商业化，造成了瓶颈，使得现有疗法无法有效地惠及目标患者群体。

监管核准和报销系统之间的摩擦导致患者获得治疗的时间显着延迟，实际上缩短了製药公司实现产生收入的时间。资金筹措的延迟阻碍了持续投资，并限制了市场服务已确诊患者群体的能力。这种延迟用药的趋势在主要地区均有体现：根据欧洲製药工业协会联合会（EFPIA）的数据，截至2024年，欧洲市场患者在获得监管核准后获得创新药物的平均等待时间已达578天。这些漫长的报销延迟凸显了药物可及性挑战的严峻性，并持续限制全球市场的规模化发展。

市场趋势

新一代长效酵素疗法的进步正在重塑市场格局。这些经过基因工程改造的蛋白质具有较低的免疫抗原性和更长的半衰期，可取代传统的重组酵素。这种转变减轻了传统疗法频繁给药的沉重负担，从而改善了临床疗效并提高了患者的长期依从性。随着医疗机构越来越重视疗效更佳、使用更便利的治疗方法，这些先进生物製药的应用速度正在加速。根据赛诺菲于2025年4月发布的《2025年第一第一季财务业绩报告》，其新一代疗法Nexiazyme第一季的销售额达到1.95亿欧元，年成长26.3%，这主要得益于活性化的患者从传统标准治疗方法转向使用此类疗法。

同时，Chaperone介导的联合治疗正被引入作为一种重要策略，以解决外源性酵素在血液循环中的不稳定性问题。合併使用药理Chaperone可以稳定治疗性酶，使更高浓度的活性蛋白能够到达标靶溶小体。这对于难治性疾病表型尤其有效。这种双机制方法透过满足罕见疾病领域尚未满足的需求（在这些领域，单药疗法缺乏持久性），已被证明具有商业性可行性。根据Amicus Therapeutics公司于2025年2月发布的“2024财年全年财务报告”，新型联合治疗“Pombility”和“Opfolder”在2024财年的销售额总合达到7020万美元，证实了市场对这种协同治疗方法的强劲需求。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球酵素替代疗法市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 副产品（加尔硫酸酶、维拉葡糖苷酶α、拉罗尼酶、阿斯福他酶α、其他）
  • 疾病类型（外分泌胰臟功能不全（EPI）、庞贝氏症、谢伊症候群、马罗托-拉米氏症候群、高雪氏症、其他）
  • 依给药途径（口服、肠外、其他）
  • 依最终使用者（医院/诊所、门诊手术中心、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美酵素替代疗法市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲酵素替代疗法市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区酵素替代疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲酵素替代疗法市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲酵素替代疗法市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球酵素替代疗法市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Takeda pharmaceutical Company Ltd.
• Leadiant Biosciences Inc.
• Biomarin Pharmaceuticals Inc.
• Genzyme Corporation
• Pfizer Inc.
• Shire plc
• Sigma-Tau Pharmaceuticals, Inc
• Essential Pharmaceuticals Limited
• Merck KGa
• AbbVie Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Enzyme Replacement Therapy Market is projected to expand from USD 10.73 Billion in 2025 to USD 16.85 Billion by 2031, registering a compound annual growth rate of 7.81%. Enzyme Replacement Therapy serves as a critical therapeutic intervention by substituting absent or deficient enzymes, primarily for patients suffering from rare genetic conditions such as lysosomal storage diseases. The market's growth is fundamentally anchored by the increasing prevalence of diagnosed genetic disorders, breakthroughs in recombinant DNA technology that facilitate scalable human enzyme production, and supportive government regulations like orphan drug designations. These drivers collectively sustain a robust development pipeline, fostering market expansion by addressing previously unmet medical needs within underserved patient populations.

However, the sector faces a substantial obstacle in the form of high costs related to the development and administration of these therapies, which frequently result in reimbursement difficulties and limited patient access. Despite these financial hurdles, the industry remains deeply committed to innovation. According to the Pharmaceutical Research and Manufacturers of America, in 2024, there were over 560 novel medicines in development for rare diseases, including treatments for enzyme deficiency disorders, demonstrating a sustained investment in resolving these complex medical conditions.

Market Driver

Regulatory approval pathways and favorable orphan drug designations act as significant catalysts for market growth by reducing the financial risks involved in developing treatments for rare conditions. Regulatory bodies offer essential incentives, including market exclusivity, tax credits for clinical trials, and accelerated review processes, which motivate pharmaceutical companies to target enzyme deficiency disorders despite the small size of patient populations. This support is clearly reflected in recent approval trends, where agencies prioritize therapies for underserved conditions. For instance, the FDA Center for Drug Evaluation and Research noted in its 'New Drug Therapy Approvals 2023' report from January 2024 that 28 of the 55 novel drugs approved in 2023 were designated as orphan drugs, highlighting the crucial role these pathways play in commercializing new rare disease therapies.

Simultaneously, robust clinical trial pipelines and strategic R&D investments are enhancing the availability and efficacy of enzyme replacement therapies. Pharmaceutical developers are increasingly directing resources toward next-generation formulations that provide better tissue targeting and stability, while also aggressively expanding their market footprint through organic growth and acquisitions. This momentum is generating significant financial returns and broadening global patient access. As reported by Chiesi Group in their '2023 Annual Report' in April 2024, the company's Rare Diseases Business Unit achieved sales of €540 million, representing a 65% growth at constant exchange rates due to portfolio expansion. Similarly, BioMarin Pharmaceutical Inc. announced in February 2024 that total revenues for the full year 2023 reached $2.42 billion, a 15% increase compared to the prior year, underscoring the sector's financial health.

Market Challenge

The substantial costs associated with developing and administering Enzyme Replacement Therapy (ERT) create major reimbursement hurdles that directly impede market expansion. Because these complex biological treatments are difficult to manufacture and target small patient populations, they often command high per-patient prices that place a significant strain on healthcare budgets. Consequently, both private and public payers frequently implement strict cost-containment measures, such as prolonged price negotiations and restrictive coverage criteria. These financial barriers obstruct the seamless commercialization of approved therapies, creating a bottleneck where available treatments fail to reach the intended patient base efficiently.

This friction between regulatory approval and reimbursement results in considerable delays in patient access, effectively shortening the revenue-generating window for pharmaceutical companies. The lag in securing funding discourages sustained investment and limits the market's capacity to serve the diagnosed population. This trend of delayed availability is quantifiable in key regions; according to the European Federation of Pharmaceutical Industries and Associations, in 2024, the average waiting time for patients to access innovative new medicines following regulatory approval reached 578 days across European markets. Such extended reimbursement delays highlight the severity of the access challenge, which continues to suppress the scalable expansion of the global market.

Market Trends

The market is being reshaped by the advancement of next-generation long-acting enzyme variants, which are replacing standard recombinant enzymes with engineered proteins that offer reduced immunogenicity and extended half-lives. This shift addresses the significant burden of frequent infusions associated with legacy therapies, thereby improving clinical outcomes and long-term patient adherence. As healthcare providers increasingly prioritize treatments that offer superior efficacy and convenience, the adoption rates for these advanced biologics have accelerated. According to Sanofi's 'Q1 2025 Results' report from April 2025, sales for the next-generation therapy Nexviazyme reached €195 million in the first quarter, marking a 26.3% increase driven by the active transition of patients from older standard-of-care regimens.

Simultaneously, the integration of chaperone-mediated combination therapies is gaining traction as a critical strategy to address the instability of exogenous enzymes in the bloodstream. By co-administering pharmacological chaperones, manufacturers can stabilize the therapeutic enzyme, ensuring that higher levels of active protein reach the target lysosomes, which is particularly effective for difficult-to-treat disease phenotypes. This dual-mechanism approach is proving its commercial viability by meeting unmet needs in the rare disease space where monotherapies have historically lacked durability. According to Amicus Therapeutics in their 'Full-Year 2024 Financial Results' report from February 2025, net product sales for the novel combination therapy Pombiliti and Opfolda totaled $70.2 million for the full year 2024, underscoring the strong market uptake of this synergistic treatment modality.

Key Market Players

• Takeda pharmaceutical Company Ltd.
• Leadiant Biosciences Inc.
• Biomarin Pharmaceuticals Inc.
• Genzyme Corporation
• Pfizer Inc.
• Shire plc
• Sigma-Tau Pharmaceuticals, Inc
• Essential Pharmaceuticals Limited
• Merck KGa
• AbbVie Inc

Report Scope

In this report, the Global Enzyme Replacement Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Enzyme Replacement Therapy Market, By Products

• Galsulfase
• Velaglucerase Alfa
• Laronidase
• Asfotasealfa
• Others

Enzyme Replacement Therapy Market, By Diseases

• Exocrine Pancreatic Insufficiency (EPI)
• Pompe Disease
• Scheie Syndrome
• Maroteaux-Lamy Syndrome
• Gaucher Disease
• Others

Enzyme Replacement Therapy Market, By Route of Administrations

• Oral
• Parenteral
• Others

Enzyme Replacement Therapy Market, By End User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Enzyme Replacement Therapy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Enzyme Replacement Therapy Market.

Available Customizations:

Global Enzyme Replacement Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Enzyme Replacement Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Products (Galsulfase, Velaglucerase Alfa, Laronidase, Asfotasealfa, Others)
  • 5.2.2. By Diseases (Exocrine Pancreatic Insufficiency (EPI), Pompe Disease, Scheie Syndrome, Maroteaux-Lamy Syndrome, Gaucher Disease, Others)
  • 5.2.3. By Route of Administrations (Oral, Parenteral, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Enzyme Replacement Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Products
  • 6.2.2. By Diseases
  • 6.2.3. By Route of Administrations
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Enzyme Replacement Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Products
      • 6.3.1.2.2. By Diseases
      • 6.3.1.2.3. By Route of Administrations
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Enzyme Replacement Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Products
      • 6.3.2.2.2. By Diseases
      • 6.3.2.2.3. By Route of Administrations
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Enzyme Replacement Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Products
      • 6.3.3.2.2. By Diseases
      • 6.3.3.2.3. By Route of Administrations
      • 6.3.3.2.4. By End User

7. Europe Enzyme Replacement Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Products
  • 7.2.2. By Diseases
  • 7.2.3. By Route of Administrations
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Enzyme Replacement Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Products
      • 7.3.1.2.2. By Diseases
      • 7.3.1.2.3. By Route of Administrations
      • 7.3.1.2.4. By End User
  • 7.3.2. France Enzyme Replacement Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Products
      • 7.3.2.2.2. By Diseases
      • 7.3.2.2.3. By Route of Administrations
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Enzyme Replacement Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Products
      • 7.3.3.2.2. By Diseases
      • 7.3.3.2.3. By Route of Administrations
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Enzyme Replacement Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Products
      • 7.3.4.2.2. By Diseases
      • 7.3.4.2.3. By Route of Administrations
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Enzyme Replacement Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Products
      • 7.3.5.2.2. By Diseases
      • 7.3.5.2.3. By Route of Administrations
      • 7.3.5.2.4. By End User

8. Asia Pacific Enzyme Replacement Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Products
  • 8.2.2. By Diseases
  • 8.2.3. By Route of Administrations
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Enzyme Replacement Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Products
      • 8.3.1.2.2. By Diseases
      • 8.3.1.2.3. By Route of Administrations
      • 8.3.1.2.4. By End User
  • 8.3.2. India Enzyme Replacement Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Products
      • 8.3.2.2.2. By Diseases
      • 8.3.2.2.3. By Route of Administrations
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Enzyme Replacement Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Products
      • 8.3.3.2.2. By Diseases
      • 8.3.3.2.3. By Route of Administrations
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Enzyme Replacement Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Products
      • 8.3.4.2.2. By Diseases
      • 8.3.4.2.3. By Route of Administrations
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Enzyme Replacement Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Products
      • 8.3.5.2.2. By Diseases
      • 8.3.5.2.3. By Route of Administrations
      • 8.3.5.2.4. By End User

9. Middle East & Africa Enzyme Replacement Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Products
  • 9.2.2. By Diseases
  • 9.2.3. By Route of Administrations
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Enzyme Replacement Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Products
      • 9.3.1.2.2. By Diseases
      • 9.3.1.2.3. By Route of Administrations
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Enzyme Replacement Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Products
      • 9.3.2.2.2. By Diseases
      • 9.3.2.2.3. By Route of Administrations
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Enzyme Replacement Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Products
      • 9.3.3.2.2. By Diseases
      • 9.3.3.2.3. By Route of Administrations
      • 9.3.3.2.4. By End User

10. South America Enzyme Replacement Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Products
  • 10.2.2. By Diseases
  • 10.2.3. By Route of Administrations
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Enzyme Replacement Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Products
      • 10.3.1.2.2. By Diseases
      • 10.3.1.2.3. By Route of Administrations
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Enzyme Replacement Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Products
      • 10.3.2.2.2. By Diseases
      • 10.3.2.2.3. By Route of Administrations
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Enzyme Replacement Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Products
      • 10.3.3.2.2. By Diseases
      • 10.3.3.2.3. By Route of Administrations
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Enzyme Replacement Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Takeda pharmaceutical Company Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Leadiant Biosciences Inc.
• 15.3. Biomarin Pharmaceuticals Inc.
• 15.4. Genzyme Corporation
• 15.5. Pfizer Inc.
• 15.6. Shire plc
• 15.7. Sigma-Tau Pharmaceuticals, Inc
• 15.8. Essential Pharmaceuticals Limited
• 15.9. Merck KGa
• 15.10. AbbVie Inc

16. Strategic Recommendations

17. About Us & Disclaimer